Skip to content

Access Intact PTH assay on the DxI 9000 Access Immunoassay… recallZ-0673-2025 · Beckman Coulter Inc. · initiated Nov 8, 2024

Open, Classified

Is my device affected?

  1. Compare the model, catalog and lot or serial numbers on your device or its packaging with the code information below. A recall usually covers only specific models or lots.
  2. If yours is listed, follow the instructions from Beckman Coulter Inc. or your healthcare provider. The company's action is summarized under what the company is doing.
  3. Do not stop using a prescribed or implanted device on your own — talk to your healthcare provider first.

Where to find your model and lot numbers · What recall classes and statuses mean

Why it was recalled

The reason for the recall is that EDTA and lithium heparin plasma samples that are stored in the DxI 9000 Access Immunoassay Analyzer sample wheel for a prolonged period before performing the intact PTH (parathyroid hormone) test may produce falsely decreased intact parathyroid hormone results. This could lead to a missed diagnosis, a delay in treatment, or inappropriate clinical management, depending upon the patient s clinical condition.

FDA root cause category: Process design

What the company is doing

On November 8, 2024, the firm notified affected customers via URGENT MEDICAL DEVICE RECALL letters that the affected assay may produce falsely decreased results if EDTA and lithium heparin plasma samples are stored in the DxI 9000 Access Immunoassay Analyzer sample wheel for a prolonged period before performing the test. Access Intact PTH assay Routine Mode and Intraoperative Mode users can select any of the following options: . Use serum as the sample type. . Perform testing on an alternate methodology, such as the Access 2 or UniCel DxI 600 or 800 Immunoassay Analyzers. . Continue to use EDTA and/or lithium heparin plasma sample types if the tests are completed within the timeframes listed below upon sample presentation to the DxI 9000 Access Immunoassay Analyzer (see page 3 for instructions): o Access Intact PTH assay Routine Mode: 25 minutes. o Access Intact PTH assay Intraoperative Mode: 20 minutes. . Beckman Coulter recommends sharing the content of this letter with your laboratory and/or medical director regarding the need to perform a retrospective review of the patient results generated from Access Intact PTH Routine Mode plasma samples on the DxI 9000 to determine if retesting is necessary.

Recall details

Recall number
Z-0673-2025
Status
Open, Classified
Initiated by the company
Nov 8, 2024
Posted by the FDA
Dec 11, 2024
Recalling firm
Beckman Coulter Inc.
Quantity
31 US; 167 OUS
Product code
CEW
FDA submissions
K232791
Distribution
Foreign distribution to Albania, Australia, Austria, Bahrain, Belgium, Brazil, C¿te d'Ivoire, Croatia, Czechia, Egypt, France, Germany, Ghana, Hungary, India, Ireland, Israel, Italy, Kazakhstan, Kuwait, Malaysia, Netherlands, New Zealand, Poland, Portugal, Slovakia, South Africa, S. Korea, Spain, Switzerland, Taiwan, United Kingdom of Great Britain and Northern Ireland.

Product description

Access Intact PTH assay on the DxI 9000 Access Immunoassay Analyzer, Catalog number A16972, for the quantitative determination of intact parathyroid hormone (parathyrin, PTH) levels in human serum and plasma.

Code information (models, lots, serial numbers)

UDI-DI 15099590201937 Lots 338921 339071 372223 439138 439205 439206 439207 439650 439801 439889 440026 440090 472012 472092 472136 472154

Devices named in this recall

1 device in the FDA device registry whose identifier appears in the recall's code information.

Sources and updates

How recalls are matched to devices · Editorial policy · Report an error on this page